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Abstract
Molecular markers in bronchial fluids may contribute to the diagnosis of lung cancer. We
previously observed a significant increase of C4d-containing complement degradation frag-
ments in bronchoalveolar lavage (BAL) supernatants from lung cancer patients in a cohort
of 50 cases and 22 controls (CUN cohort). The present study was designed to determine
the diagnostic performance of these complement fragments (hereinafter jointly referred as
C4d) in bronchial fluids. C4d levels were determined in BAL supernatants from two indepen-
dent cohorts: the CU cohort (25 cases and 26 controls) and the HUVR cohort (60 cases and
98 controls). A series of spontaneous sputum samples from 68 patients with lung cancer
and 10 controls was also used (LCCCIO cohort). Total protein content, complement C4,
complement C5a, and CYFRA 21-1 were also measured in all cohorts. C4d levels were sig-
nificantly increased in BAL samples from lung cancer patients. The area under the ROC
curve was 0.82 (95%CI = 0.71–0.94) and 0.67 (95%CI = 0.58–0.76) for the CU and HUVR
cohorts, respectively. In addition, unlike the other markers, C4d levels in BAL samples were
highly consistent across the CUN, CU and HUVR cohorts. Interestingly, C4d test markedly
increased the sensitivity of bronchoscopy in the two cohorts in which cytological data were
available (CUN and HUVR cohorts). Finally, in the LCCCIO cohort, C4d levels were higher
in sputum supernatants from patients with lung cancer (area under the ROC curve: 0.7;
95%CI = 0.56–0.83). In conclusion, C4d is consistently elevated in bronchial fluids from
lung cancer patients and may be used to improve the diagnosis of the disease.
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Introduction
Lung cancer is the leading cause of cancer-related death worldwide [1]. The overall five-year
survival rate for lung cancer is approximately 15–20%, and less than 5% in metastatic cases [2].
One of the reasons for such a dismal outcome is the lack of effective techniques for early diag-
nosis of the disease. Currently, lung cancer diagnosis involves the combination of radiological
and histological analyses of lesions. Flexible bronchoscopy represents a relatively noninvasive
initial diagnostic test in individuals with suspected disease, and is the primary diagnostic tool
in patients with centrally located lung cancer. Bronchoscopic techniques for the diagnosis of
lung cancer include cytological examination of specimens from bronchial biopsy, bronchial
brush, bronchial wash, and bronchoalveolar lavage (BAL) [3, 4]. Specificity of cytology of bron-
choscopic material is 100%; however, sensitivity remains low, especially in more peripheral le-
sions, for which more invasive diagnostic procedures are routinely needed [5]. Thus, there is a
clinical demand of adjunct markers that may improve the sensitivity of lung cancer
diagnostic procedures.
Multiple biomarkers detectable in bronchial fluids from lung cancer patients have been pro-
posed [6, 7, 8, 9, 10, 11, 12]. Recently, we have shown that lung cancer cells efficiently activate
the classical pathway of complement. As a consequence, C4d, a stable split product of this path-
way, is found elevated in plasma and BAL samples from lung cancer patients [13]. The aim of
the present study was to validate our previous observation in independent case-control cohorts.
We also aimed to compare the diagnostic performance of C4d with other potential diagnostic
biomarkers: CYFRA 21-1, total protein, C4, and C5a. CYFRA 21-1 has long been proposed as a
lung cancer biomarker in bronchial fluids [7, 14], plasma proteins are increased in BAL fluids
from lung cancer patients [15], C4 is an abundant plasma protein from which C4d is generated
after complement activation [16], and C5a is an active complement fragment increased in plas-
ma samples from patients with non-small cell lung cancer [17]. Our results suggest that the de-
termination of C4d in airway fluids outperforms the other markers and may be useful in the
diagnostic workup of patients with lung cancer.
Materials and Methods
Clinical samples
The study included three cohorts of BAL samples and one of sputum specimens. BAL fluids
were obtained from subjects undergoing diagnostic bronchoscopy and stored at −80°C. The
procedure for BAL collection has been previously described [15]. The cohort from Clinica Uni-
versidad de Navarra (CUN) included BAL samples from 50 patients with lung malignancies
and 22 patients with nonmalignant lung diseases. More details of this cohort have been previ-
ously reported [15]. The cohort from Charité-Universitätsmedizin (CU) included BAL speci-
mens from 25 lung cancer patients and 26 control subjects. These control individuals
underwent bronchoscopy for non-malignant airway diseases such as infection, benign airway
stenosis or sarcoidosis. No additional data were available from this cohort. The third cohort
was obtained at the Hospital Universitario Virgen del Rocio (HUVR) and included BAL fluids
from 60 lung cancer patients and 98 control patients. The characteristics of these patients are
shown in Table 1. Bronchoscopy was required in control patients due to the presence of he-
moptysis or a pulmonary lesion in the chest-x ray or CT scan. Finally, the Lung Cancer Clinic
of Catalan Institute of Oncology (LCCCIO) cohort of sputum specimens included 68 samples
from lung cancer patients and 10 samples from healthy individuals. Samples were collected
after spontaneous expectoration, diluted in 10 ml of saline, extensively vortexed, and stored at
−80°C. All study protocols were performed according to the Declaration of Helsinki, were
C4d in Bronchial Fluids for Lung Cancer Diagnosis
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approved by the Research Ethics Committee of the University of Navarra (Institutional Review
Board#015-2014), and all patients gave written informed consent. Lung tumors were classified
using the WHO 2004 classification and the International System for Staging Lung Cancer
[18, 19].
Marker measurements
C4d-containing fragments were measured by an enzyme-linked immunosorbent assay (Qui-
del). This assay recognizes all C4d-containing fragments of activated C4 (C4b, iC4b and/or
C4d), which together are referred to in this paper as C4d. Quantitative enzyme-linked immu-
nosorbent assays were also used for the determinations of C4 (Assaypro), C5a (R&D), and
CYFRA 21-1 (DRG International). BAL samples were diluted 1:10, 1:1000, 1:100, and 1:25 for
the analysis of C4d, C4, C5a, and CYFRA 21-1, respectively. Sputum specimens were diluted
1:4 for C4d quantitation. Total protein was measured using the BCA protein assay (Pierce). All
biomarker measurements were performed retrospectively by laboratory personnel not aware of
Table 1. Demographics and C4d levels in BAL fluids of patients from the HUVR cohort.
Characteristics Lung cancer patients Non-cancer patients
n C4d (μg/ml) Median (IQR) P1 n C4d (μg/ml) Median (IQR) P1
Sex
Male 54 0.19 (0.15–0.26) 0.232 79 0.16 (0.14–0.18) 0.562
Female 6 0.15 (0.14–0.59) 19 0.15 (0.14–0.17)
Age (years)
60 21 0.17 (0.15–0.22) 0.329 46 0.15 (0.14–0.17) 0.300
>60 39 0.21 (0.15–0.31) 52 0.16 (0.15–0.18)
Smoking status
Former 34 0.21 (0.15–0.52) 0.065 59 0.16 (0.15–0.18) 0.058
Current 26 0.17 (0.15–0.21) 39 0.15 (0.14–0.16)
Pack-years
35 7 0.21 (0.17–0.27) 0.199 23 0.16 (0.15–0.18) 0.545
>35 37 0.18 (0.15–0.24) 32 0.15 (0.14–0.18)
Not available 16 0.22 (0.16–0.72) 43 0.16 (0.14–0.17)
COPD
No 43 0.17 (0.15–0.18) 0.849
Yes 18 0.16 (0.15–0.19)
Not available 37 0.15 (0.14–0.17)
Histology
AC 9 0.15 (0.14–0.17) 0.158
SCC 28 0.20 (0.16–0.29)
SCLC 13 0.22 (0.14–0.64)
Other 7 0.20 (0.17–1.10)
Not available 3 0.21 (0.19–0.74)
Stage
I-III 24 0.18 (0.15–0.25) 0.249
IV 29 0.20 (0.16–0.53)
Not available 7 0.16 (0.14–0.22)
1Mann-Whitney U test, except for comparison of histologies (Kruskal-Wallis test).
doi:10.1371/journal.pone.0119878.t001
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the diagnosis. All procedures were carried out in a single laboratory following the
manufacturers’ instructions.
Statistical analyses
SPSS 15.0 software was used for statistical analysis. Normality was assessed using Shapiro-Wilk
test. Two-sided Mann-Whitney U test or Kruskal-Wallis H test were used to compare non-
normally distributed data from two or more groups, respectively. Marker levels are shown as
median (interquartile range). Receiver operating characteristic (ROC) curves were generated in
order to evaluate the diagnostic performance of the biomarkers. Statistical differences between
the area under the ROC curves and a reference area under the ROC curve of 0.5 were calculated
with a z-score test. Ninety five percent confidence intervals were also calculated. P values less
than 0.05 were considered statistically significant.
Results
C4d levels in BAL supernatants from lung cancer patients
In a previous study we found that the levels of C4d-containing complement degradation frag-
ments (jointly referred as C4d) were increased in BAL samples from lung cancer patients when
compared to samples from patients with nonmalignant lung diseases [13]. Briefly, C4d levels,
shown as median (interquartile range), were 0.26 (0.11–0.54) μg/ml in the lung cancer group
and 0.11 (0.11–0.23) μg/ml in the control group (P<0.001). The area under the ROC curve was
0.73 (95%CI = 0.61–0.84; P = 0.002). This analysis was performed on BAL samples from a co-
hort of patients herein denoted as CUN cohort. The characteristics of these patients have al-
ready been published [15]. In the present study, we sought to validate this result using two
independent cohorts of BAL samples: the HUVR and the CU cohorts. In this latter cohort, C4d
levels in lung cancer specimens and controls were 0.19 (0.11–0.84) and 0.11 (0.11–0.13) μg/ml,
respectively (P<0.001; Fig. 1A). The area under the ROC curve was 0.82 (95%CI = 0.71–0.94;
P<0.001). In the HUVR cohort, C4d levels in the cancer group were 0.18 (0.15–0.26) μg/ml,
and in the control group were 0.16 (0.14–0.18) μg/ml (P<0.001; Fig. 1B). The area under the
ROC curve was 0.67 (95%CI = 0.58–0.76; P<0.001). In this cohort, C4d levels tended to be
higher in BAL fluids from small cell lung cancer (SCLC) patients or former smokers, although
the differences did not reach statistical significance (Table 1). In accordance with this observa-
tion, in our previous study (CUN cohort) we found a significant increase of C4d in former
smokers in the cancer group, and a trend towards higher C4d levels in patients with SCLC
[13].
Performance comparison of C4d with other molecular markers
In order to assess the usefulness of C4d as a diagnostic biomarker in BAL fluids, we compared
its performance with other potential diagnostic molecular markers. For this purpose, we mea-
sured the levels of CYFRA 21-1, C4 and C5a in the CUN, CU, and HUVR cohorts. Except for
CYFRA 21-1 and C5a in the CUN cohort, and for C5a in the HUVR cohort, the levels of all the
markers were significantly increased in lung cancer patients (Table 2).
The accumulation of plasma proteins in the tumor interstitium is a common feature of solid
tumors [20]. In fact, plasma proteins can be found in BAL fluids from lung cancer patients
[15]. In agreement with this observation, in the three cohorts, the levels of total proteins were
found increased in BAL fluids from lung cancer patients as compared to controls (Table 2). To
evaluate the possibility that C4d, CYFRA 21-1, C4, and C5a were found in BAL samples as a
mere consequence of their extravasation from blood, we analyzed the enrichment of these
C4d in Bronchial Fluids for Lung Cancer Diagnosis
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markers in BAL samples from lung cancer patients with respect to blood using total protein
content as reference (Table 3). Very similar proportions of C4 were found in BAL samples and
blood, which suggests that the presence of this complement protein in the tumor
Fig 1. Quantification of the complement component C4d in BAL supernatants from two cohorts (CU
and HUVR) of patients with lung cancer and control individuals. A) C4d levels and ROC curve from BAL
supernatants of the CU cohort. B) C4d levels and ROC curve from BAL samples of the HUVR cohort.
Differences between groups were evaluated using the Mann-Whitney U test. The areas under the ROC
curves (AUC) and their associated P values are indicated.
doi:10.1371/journal.pone.0119878.g001
Table 2. C4d, CYFRA 21-1, C5a, C4, and total protein levels in BAL fluids from individuals of the CUN, CU and HUVR cohorts.
CUN cohort CU cohort HUVR cohort
Control
(n = 22)
Lung cancer
(n = 50)
Control
(n = 26)
Lung cancer
(n = 25)
Control
(n = 98)
Lung cancer
(n = 60)
Marker Median (IQR) Median (IQR) P1 Median
(IQR)
Median (IQR) P1 Median
(IQR)
Median (IQR) P1
C4d (μg/ml) 0.11 (0.11–
0.23)
0.26 (0.11–0.54) <0.001 0.11 (0.11–
0.13)
0.19 (0.11–0.84) <0.001 0.16 (0.14–
0.18)
0.18 (0.15–0.26) <0.001
CYFRA 21–1
(μg/ml)
0.07 (0.02–
0.25)
0.09 (0.04–0.19) 0.616 0.02 (0.02–
0.03)
0.05 (0.03–0.13) 0.001 0.01 (0–0.02) 0.02 (0.01–0.05) 0.001
C5a (ng/ml) 4.48 (0.63–
14.21)
6.26 (2.36–
20.09)
0.156 0 (0–0.05) 0.54 (0.04–3.42) <0.001 0 (0–0.82) 0.16 (0–0.59) 0.580
C4 (μg/ml) 0.87 (0.45–
3.24)
3.77 (0.98–6.56) 0.022 0.15 (0.05–
0.31)
1.53 (0.50–9.31) <0.001 0.16 (0.05–
0.43)
0.47 (0.09–2.52) 0.001
Total protein
(mg/ml)
0.24 (0.12–
0.83)
0.74 (0.25–1.43) 0.008 0.14 (0.05–
0.41)
0.88 (0.31–1.30) <0.001 0 (0–0.22) 0.37 (0.19–0.84) <0.001
1Mann-Whitney U test
doi:10.1371/journal.pone.0119878.t002
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microenvironment is mainly due to its extravasation. However, CYFRA 21-1, C4d, and C5a
showed a markedly higher proportion in BAL fluids, suggesting a local production of these
molecules within the tumor microenvironment.
A factor that strongly influences the performance and usefulness of a diagnostic marker is
its consistency across different patient populations. We therefore compared the levels of the
four molecular markers across the three independent cohorts. As shown in Fig. 2, significant
differences among lung cancer patients in the CUN, CU, and HUVR cohorts were observed for
CYFRA 21–1, C5a, C4, and total protein (P<0.001, P<0.001, P<0.001, and P = 0.029, respec-
tively). We observed higher levels of these markers in the CUN cohort, although the reason for
this difference is unclear. Nevertheless, the levels of C4d were remarkably similar across the
three series with no significant differences between them (P = 0.922). The consistency of C4d
levels allowed us to propose C4d cut-off values with satisfactory sensitivity and specificity
across the three cohorts. For example, with a cut-off value of 0.18 μg/ml, the sensitivity in the
diagnosis of lung cancer was 62%, 52%, and 53%, with a specificity of 73% (odds ratio (OR) =
4.35, 95%CI = 1.45–13.05, P = 0.009), 100%, and 80% (OR = 4.46, 95%CI = 2.20–9.03,
P<0.001) in the CUN, CU, and HUVR cohorts, respectively. When pooling the three studies
Table 3. Enrichment of the markers in BAL fluids from lung cancer patients as compared to their presence in blood.
Blood BAL
Marker concentration Mean
(μg/ml)*
Ratio marker/total
protein
Marker concentration Mean
(μg/ml)
Ratio marker/total
protein
Marker enrichment in
BAL**
CUN cohort
Total
protein
79000 1 1520 1 1
C4 410 5.2 x 10−3 6.04 3.9 x 10−3 0.77
C4d 3.5 4.4 x 10−5 0.61 4 x 10−4 9.06
C5a 0.028 3.5 x 10−7 0.012 7.9 x 10−6 22.27
CYFRA
21-1
0.013 1.6 x 10−7 0.13 8.5 x 10−5 520
CU cohort
Total
protein
79000 1 870 1 1
C4 410 5.2 x 10−3 5.29 6.1 x 10−3 1.17
C4d 3.5 4.4 x 10−5 0.64 7.3 x 10−4 16.60
C5a 0.028 3.5 x 10−7 0.0017 1.9 x 10−6 5.51
CYFRA
21-1
0.013 1.6 x 10−7 0.2 2.3 x 10−4 1397
HUVR
cohort
Total
protein
79000 1 610 1 1
C4 410 5.2 x 10−3 2.21 3.6 x 10−3 0.70
C4d 3.5 4.4 x 10−5 0.57 9.3 x 10−4 21.09
C5a 0.028 3.5 x 10−7 0.0007 1.1 x 10−6 3.24
CYFRA
21-1
0.013 1.6 x 10−7 0.07 1.1 x 10−4 697
*Average blood concentrations of C4, C4d, C5a, and CYFRA in lung cancer patients were obtained from previous reports [13], [17], [34, 35]. Total protein
in blood was calculated in our laboratory using 134 plasma samples from lung cancer patients.
**Calculated as the ratio of the marker in BAL ﬂuids divided by the ratio of the marker in blood.
doi:10.1371/journal.pone.0119878.t003
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together, the sensitivity was 56% and the specificity was 82% (OR = 5.94, 95%CI = 3.45–10.24,
P<0.001). In summary, we conclude that C4d is produced within the lung tumor microenvi-
ronment, resulting in a consistent increase of this molecule in BAL fluids from lung cancer
patients.
Determination of C4d in BAL supernatants as an adjunct to cytology for
lung cancer diagnosis
We next assessed the capacity of C4d determination to improve the diagnostic performance of
the cytological examination of bronchoscopic material, a technique with high specificity but
low sensitivity. For this purpose we used the two cohorts from which we had cytology data:
CUN and HUVR cohorts. In the CUN cohort, cytological examination of BAL samples yielded
a specificity of 100% and a sensitivity of 32%. Examining the diagnostic value of the informa-
tion provided by C4d, we found that this marker was significantly increased in both cytolog-
ically positive and negative BAL supernatants from lung cancer patients (Fig. 3). The levels of
Fig 2. Comparison of the levels of the different markers across the three independent cohorts of BAL
supernatants from lung cancer patients. A) C4d (data from the CUN cohort were published previously
[13]). B) CYFRA 21–1. C) C5a. D) C4. E) Total protein. P values were calculated using the Kruskal-
Wallis test.
doi:10.1371/journal.pone.0119878.g002
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C4d in the control group were 0.11 (0.11–0.23) μg/ml and increased to 0.33 (0.23–0.5) μg/ml in
cytologically positive samples (P<0.001), and to 0.24 (0.11–0.62) μg/ml in cytologically nega-
tive samples (P = 0.018). The areas under the ROC curves were 0.85 (95%CI = 0.71–0.98;
P<0.001) and 0.67 (95%CI = 0.53–0.81; P = 0.033), respectively. The diagnostic performance
of C4d was better in cytologically positive BAL samples, although no significant differences
were found between these two groups (P = 0.187). This result suggests that the determination
of C4d levels may be useful even in cases in which the cytological examination of BAL fluids is
reported as negative. In fact, using the cut-off value previously established (0.18 μg/ml), 18 out
of 34 lung cancers reported as negative by cytological examination were classified as positive by
C4d determination, increasing the sensitivity in the diagnosis of lung cancer from 32% to 68%,
with a specificity of 73%. This observation was validated with the analysis of the HUVR cohort.
Cytological examination in this cohort yielded a sensitivity of 32% and a specificity of 100%.
The content of C4d in BAL supernatants significantly increased in both cytologically positive
and negative lung cancer BAL supernatants when compared with control subjects (Fig. 4).
C4d levels in the control group were 0.16 (0.14–0.18) μg/ml, and increased to 0.22 (0.16–0.40)
μg/ml in cytologically positive samples (P<0.001), and to 0.18 (0.15–0.23) μg/ml in cytological-
ly negative samples (P = 0.017). The areas under the ROC curves were 0.76 (95%CI = 0.63–
0.88; P<0.001) and 0.63 (95%CI = 0.52–0.74; P = 0.011), respectively. No significant differ-
ences in C4d levels were observed between cytologically positive and negative BAL samples
(P = 0.123). With a cut-off value of 0.18 μg/ml, 19 out of 41 cancers reported as negative by cy-
tology were classified as positive by C4d, increasing the sensitivity in the diagnosis of lung can-
cer from 32% to 63%, with a specificity of 80%.
Fig 3. C4d levels and ROC curves from cytologically positive (A) and negative (B) lung cancer BAL
supernatants of the CUN cohort. P values were calculated using the Mann-Whitney U test. The areas
under the ROC curves (AUC) and their associated P values are indicated.
doi:10.1371/journal.pone.0119878.g003
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C4d levels in sputum supernatants from lung cancer patients
Diagnosis of lung cancer by examination of sputum is an attractive alternative to bronchosco-
py. In order to preliminary evaluate the utility of C4d as a diagnostic marker in this biological
specimen, C4d levels were determined in spontaneous sputum samples from lung cancer pa-
tients (n = 68) from the LCCCIO cohort. C4d levels ranged from 0.04 to 0.56 μg/ml with a me-
dian (IQR) of 0.06 (0.06–0.07) μg/ml. No significant associations were found between the
levels of the marker and clinicopathological data, such as sex, smoking status, histology
(NSCLC vs. SCLC) or stage (I-III vs. IV). Finally, we compared the levels of C4d in these spu-
tum samples with the levels in 10 healthy controls. As shown in Fig. 5, C4d levels were slightly
Fig 4. C4d levels and ROC curves from cytologically positive (A) and negative (B) lung cancer BAL
supernatants of the HUVR cohort. P values were calculated using the Mann-Whitney U test. The areas
under the ROC curves (AUC) and their associated P values are indicated.
doi:10.1371/journal.pone.0119878.g004
Fig 5. Evaluation of C4d levels in sputum specimens from lung cancer patients and control subjects.
P values were calculated using the Mann-Whitney U test. The area under the ROC curve (AUC) and its
associated P value are indicated.
doi:10.1371/journal.pone.0119878.g005
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higher in sputum supernatants from patients with lung cancer than in those from control sub-
jects (P = 0.047). The area under the ROC curve was 0.7 (95%CI = 0.56–0.83, P = 0.047). With
a 0.06 μg/ml cut-off, sensitivity and specificity were 54% and 80%, respectively. In conclusion,
C4d levels are significantly higher in spontaneous sputum samples from lung cancer patients
than in those samples from cancer-free subjects.
Discussion
In this study, we demonstrate that C4d-containing complement degradation fragments (jointly
referred as C4d) are elevated in bronchial fluids from lung cancer patients and their determina-
tion performs better than previously proposed protein biomarkers for lung cancer diagnosis.
Our conclusions are supported by four major observations: i) we have validated, in two inde-
pendent cohorts, the increase in C4d previously observed in a cohort of BAL samples from
lung cancer patients [13]; ii) no differences were observed in the levels of the marker across
BAL samples from lung cancer patients of three independent cohorts; iii) C4d quantification
improved the sensitivity of cytologic examination of BAL fluids; and iv) C4d levels were slightly
increased in sputum supernatants from lung cancer patients.
So far, the efforts to identify clinically valuable diagnostic markers for lung cancer have ei-
ther failed or had limited success. This can be explained in part by the low degree of reproduc-
ibility across independent studies due to the high genetic and phenotypic heterogeneity of lung
tumors [21]. To overcome this limitation, it has been suggested that immune-related markers
might be more homogeneous and sensitive than cancer-derived markers [22]. In this sense,
during neoplastic transformation, lung tumor cells from different histological subtypes can be
recognized by the complement system [17], [23, 24]. Complement is an important part of the
innate immune response that defends the host against non-self elements. Interestingly, due to
the elevated expression of complement inhibitors, lung cancer cells control complement activa-
tion and are resistant to complement-mediated cytotoxicity [23, 24, 25, 26, 27]. This controlled
immune response may result in a permanent release of complement fragments to the tumor
microenvironment, which would explain why C4d, a fragment originated from complement
C4, is increased in biological fluids from patients with lung cancer [13]. Interestingly, we ob-
served remarkably similar concentrations of C4d across BAL samples from the three studied
cohorts. This is a relevant point, since the standardization of measurements between different
studies is a major problem in biomarker discovery [28, 29]. In relation to the primary source of
C4d, this molecule is a proteolytic fragment of complement C4 generated after activation of the
classical complement pathway [16]. Therefore, the most plausible explanation for its presence
within the tumor microenvironment would be its local production after activation of this ca-
nonical pathway. However, we cannot rule out other mechanisms. For example, exoproteases
present in biological fluids from cancer patients can generate peptides from complement pro-
teins [30]. On the other hand, although C4d levels are also increased in plasma from lung can-
cer patients [13], the levels of the marker in bronchial fluids are noticeably higher than those
expected by extravasation, which favors the local origin of C4d.
We also found that C4d performed better than other complement-related markers, C4 and
C5a, or the proposed tumor marker CYFRA 21-1. In the case of C4, the precursor molecule for
C4d, we conclude that its presence in the airway fluids is mostly due to its extravasation from
blood. Similarly, increased levels of other extravasated plasma proteins, such as complement
factor H or albumin, were previously observed in bronchial fluids from lung cancer patients
[15]. On the other hand, our data suggest a local production of C5a, an anaphylatoxin that can
be produced by lung cancer cells [17]. However, this marker was found significantly increased
in BAL samples from lung cancer patients in only one of the three cohorts. Similar results were
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observed with CYFRA 21-1, one of the most studied lung cancer biomarkers in the literature
[7, 14]. Our data suggested a local production of CYFRA 21-1 within the tumor microenviron-
ment, but its levels across the cohorts were poorly consistent and differences between malig-
nant and non-malignant samples were not found in one of the series. These observations
suggest that C5a and CYFRA 21-1 are produced in the presence of lung tumors, but also in
the presence of non-malignant inflammatory conditions common to patients undergoing
bronchoscopy.
Given the relatively low sensitivity of the cytological examination of bronchoscopic speci-
mens, more invasive diagnostic tests are usually needed. In this context, a diagnostic procedure
useful to determine which patients with suspected lung cancer, but negative bronchoscopies,
should undergo additional diagnostic testing would be clinically relevant. In this study, the ad-
dition of C4d quantification to the diagnostic procedure increased the sensitivity of bronchos-
copy, although reduced its specificity. The reduction in specificity may limit its adoption as a
routine clinical diagnostic tool. However, the consistency of the marker across independent co-
horts of bronchial fluid samples and its better performance than previously proposed biomark-
ers encourage the integration of C4d in a panel of biomarkers to complement cytology in the
diagnosis of the disease. This is an important point since novel panels of biomarkers such as
autoantibodies, microRNAs or proteomic classifiers have yielded promising results in blood
specimens from lung cancer clinical cohorts [31, 32, 33]. Moreover, our data suggest that C4d
evaluation in non-invasive sputum samples may also be a useful tool for lung cancer diagnosis.
This observation, based on a small cohort of sputum samples, merits further evaluation in larg-
er series using more clinically relevant controls with non-malignant lung disease. Other aspects
that need to be clarified are the performance of the assay in the different histologic subtypes, as
well as the influence of smoking, and specific non-malignant respiratory conditions and treat-
ments on C4d levels. At present, we can conclude that C4d levels are consistently increased in
bronchial fluids from lung cancer patients and may complement cytology in the diagnosis of
the disease.
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